A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Red Bull got relief after Delhi High Court overturned a Food Safety and Standards Authority of India (FSSAI) order that instructed the Austrian beverage giant to drop its ‘energy drink’ label. In a recent ruling, the court made its decision after it found that the Indian food regulator did not give sufficient time to the company to present its case.

While the legal fight between the food regulator and the billion-dollar beverage giant boils down to just two words on a can, the health question is much bigger: What does drinking an energy drink like Red Bull actually do to the body?

FSSAI Vs Red Bull

FSSAI had said India does not have a notified food standard specifically defining an “energy drink”, objecting to brands like Red Bull making claims like boosting energy or enhancing focus.

The regulator's concerns also included linked to what these beverages actually contain, particularly excessive caffeine, sugar, and other controversial ingredients like taurine.

The biggest concern that the lawsuit is built upon is what causes the sudden surge of ‘energy’ after someone consumes this drink. Is it giving your body useful energy?

Also read: High Sugar, Salt Or Fat? India May Mandate Red Hexagon Labels On Food Packs

Red Bull’s Ingredients And It Does To Your Body

Caffeine

One of the main ingredients responsible for the immediate feeling of energy alertness is caffeine. Caffeine stimulates the central nervous system, making you feel more awake and less tired. But that boost does not mean the drink is providing the body with sustained energy in the nutritional sense.

Depending on the product, energy drinks can also contain substantial amounts of added sugar, which adds calories but does not make the drink healthier.

The caffeine content of energy drinks varies considerably. The US FDA notes that energy drinks can contain roughly 41 to 246 mg of caffeine per 12 fluid ounces, depending on the product.

The energy boost claim may comes from the caffeine content, which is what consumers should be mindful about. Too much caffeine can lead to faster heartbeat, palpitations, increased blood pressure, anxiety, jitters, headaches, nausea and sleep disruption. For most healthy adults, the FDA cites 400 mg of caffeine a day.

Also read: Every Extra 100g Ultra-Processed Food Linked To 14% Higher Heart Risk, 11% Higher BP Risk

Energy drinks can also temporarily increase blood pressure and cardiovascular load. A 2024 review and meta-analysis of randomised trials found that energy drinks acutely increased systolic and diastolic blood pressure in healthy adults.

Excess caffeine in young people can cause palpitations, increased heart rate and blood pressure, anxiety, sleep problems and digestive symptoms. Therefore, the FDA and medical experts advise against energy drinks for children and teenagers.

This is also why energy drinks have attracted regulatory restrictions worldwide. England, for example, plans to prohibit their sale to under-16s from April next year.

Sugar

The sugar content is another reason to be careful about how often you drink energy drinks. Regular and frequent consumption of high amounts of added sugar, through liquid calories like energy drinks, can increase overall calorie intake and contribute to weight gain and obesity.

Over time, excess sugar intake is also linked with a higher risk of metabolic problems like type 2 diabetes and fatty liver disease. For people who regularly consume these energy drinks, the concern is therefore not just the caffeine, but also how much added sugar they are consuming with each can.

Taurine

HealthAndMe previously reported that taurine may help fuel the growth of certain leukaemia cells. The research raised questions about taurine's role in blood cancer biology.

The research was about the biological behaviour of cancer cells and does not establish that taurine-laced energy drinks cause blood cancer in humans.

The bottomline is that the Delhi High Court's ruling does not mean that Red Bull has been declared healthy. It addresses whether FSSAI followed the correct procedure when restricting the “energy drink” label. So even though Red Bull can be marketed and sold as an “energy drink”, it cannot be automatically considered healthy.

A new artificial intelligence-based screening tool may be able to analyse just 20 seconds of speech to identify clues linked with type 2 diabetes.

A recent large-scale study found that the AI model could detect type 2 diabetes from short voice recordings, including when its predictions were checked against HbA1c blood-test results.

The researchers say the technology could eventually offer a quick, non-invasive way to triage patients and identify people who may need routine diabetes testing.

The researchers stress upon the fact that this is a just screening tool, not a replacement for conventional blood test for type 2 diabetes.

Can Someone’s Voice Reveal If They Have Type 2 Diabetes?

The very idea of diagnosing a disorder from voice seems strange but researchers have been studying changes in speech as key biomarkers that could give reliable clues about a particular disease.

Type 2 diabetes affect multiple physiological systems, including nerves, muscles and blood vessels. These changes could have a subtle influence on various aspects of speech, like pitch, timing and other acoustic characteristics that are not prominent enough for the human ear.

The AI does not ‘listen’ for someone saying they have diabetes. Instead, it analyses patterns in the voice recording and looks for combinations linked with type 2 diabetes.

Also read: Gut Microbiome May Reveal Diabetes Risk Before Blood Sugar Changes: Study

What Did The Researchers Find From Voice Recordings?

Researchers developed the model using 63,000 voice recordings from more than 21,000 people in the US and UK and then tested it in a separate group of 7,319 adults. Participants provided short recordings involving reading aloud from Aesop’s fables.

The model showed an area under the curve (AUC) of 0.80 when tested against self-reported type 2 diabetes. It means that the speech tool accurately assigned higher risk scores to individuals who had type 2 diabetes in 80% of the instances.

A secondary analysis of 801 participants also underwent HbA1c testing within three months of voice testing, providing an objective measure of blood sugar control. When the AI tool’s predictions were compared with those results, it achieved an AUC of 0.75 for diabetes and 0.73 for prediabetes.

Also read: Diabetes Linked To 55% Risk Of Kidney Disease, Heart Failure Or Death Within 10 Years: Study

AI Tool’s Implications In Diabetes Testing

Type 2 diabetes can remain undiagnosed for years, allowing complications to develop before treatment begins. Blood tests like fasting glucose and HbA1c are the conventional ways to diagnose diabetes. One has to go to the clinic, get their blood drawn and wait for some time to get their diabetes diagnosis.

Giedre Cepukaityte, research scientist at thymia, who will be presenting the findings at the European Association for the Study of Diabetes (EASD) in Milan, said, "This is the largest real-world study of speech-based screening for type 2 diabetes to date which also checks the model’s predictions against blood test results as well as against what people reported about their own diagnosis. Those flagged up as higher risk by the model had blood results to match.”

The advantage of voice screening could make a difference in diabetes testing. As someone can do this test without visiting a clinic, this could be the first step people undergo before proper testing. Someone flagged as being at higher risk would need a conventional blood test.

Cepukaityte added, "This has the potential to change what screening looks like. A speech sample can be taken over the phone or through an app, so we can reach far more of the people who need a blood test than current pathways do, particularly those who never get to a health check.”

A voice-based tool could make screening easier for people who do not routinely visit doctors or have difficulty accessing healthcare services. The researchers found that the voice model identified about three-quarters of type 2 diabetes cases, although it also produced false-positive results.

"Our model opens a new route to screening for diabetes. It is not a replacement for a blood test, and it should never stop anyone who thinks they need one from getting one. Our next step is to test the model in clinical settings and to understand how well it works for every group of people, because a screening tool has to work for everyone."

Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said, "More than a million people in the UK are living with undiagnosed type 2 diabetes and are missing out on the support and treatment they need to help them stay well and reduce their risk of developing devastating complications.”

She added, “AI-based technologies could help identify more people who may benefit from diagnostic blood tests, but it’s crucial that they are rigorously designed and tested to make sure no-one slips through the net.Anyone concerned about their risk of type 2 diabetes can use Diabetes UK’s free Know Your Risk tool and should speak to their healthcare team if they have concerns.”

Long associated with factors such as obesity, lifestyle and genetics, cancer can also be linked to infections. A new study published in The Lancet Oncology found that an estimated 2.3 million new cancer cases globally in 2024 — 12%, or about one in eight of all cancers diagnosed that year — were attributable to infections.

The analysis included 12 infectious agents known to cause cancer in humans, including viruses, a bacterium and parasites. It also incorporated newly established infection-cancer associations and additional cancer types caused by known carcinogenic infections, including recent evidence linking Epstein-Barr virus (EBV) with gastric cancer.

“The findings underscore the major role that infection control can play in reducing the global cancer burden,” said Dr Harriet Rumgay, a scientist in the Cancer Surveillance Branch at IARC.

“Despite progress in vaccination and screening, infection-related cancers remain a major global challenge, with the burden falling disproportionately on populations in low- and middle-income countries,” Rumgay added.

Which Infections Are Driving Cancer?

Also read: US Cancer Death Rates Fall For Men, Women: Lung Cancer Progress Drives Decline

Based on cancer burden estimates from the IARC Global Cancer Observatory database, the researchers assessed 12 infectious agents known to cause cancer: Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), EBV, Kaposi sarcoma-associated herpesvirus (KSHV), Schistosoma haematobium, human T-cell lymphotropic virus type 1 (HTLV-1), Opisthorchis viverrini, Clonorchis sinensis, Merkel cell polyomavirus and HIV.

Five of these accounted for almost all infection-linked cancer cases in 2024:

• H. pylori, the stomach bacterium, was linked to 760,000 cases, or 4% of all cancers diagnosed that year.
• HPV was linked to 750,000 cases, also accounting for 4%.
• HBV was linked to 360,000 cases, or 2%.
• EBV was linked to 260,000 cases, or 1%.
• HCV was linked to 160,000 cases, or less than 1%.

Which Countries Bear Most Of The Burden?

READ: Multicancer Blood Test Detects 17 Cancer In A Large Study: Can It Replace Mammograms & Colonoscopies?

Low- and middle-income countries accounted for 77% of all infection-linked cancer cases.

Eastern Asia recorded the largest number of infection-attributable cancer cases, with 990,000 cases — 42% of the global total — driven mainly by H. pylori and HBV.

Sub-Saharan Africa had the highest proportion of cancers linked to infection, with a quarter of all cancers in the region attributed to infectious agents. The burden was driven largely by HPV, KSHV and HIV.

The study also found that EBV is the fourth-largest infectious cause of cancer globally, ahead of HCV. This reflects growing evidence that EBV contributes not only to nasopharyngeal cancer and lymphomas but also to a proportion of gastric cancers.

How To Prevent Infection-Related Cancers

Read More: Fatty Liver, Chronic Gut Diseases And Worm Infections: India’s Changing Disease Burden

The authors said the findings underline the importance of infection control in reducing cancer rates. They highlighted several measures that are already available but remain underused, including

• HPV and hepatitis B vaccination;
• testing and treatment for HIV, H. pylori, and hepatitis B and C;
• safe injection practices;
• access to condoms
• pre-exposure prophylaxis to prevent HIV transmission;
• screening for precancerous lesions in HPV-driven cervical and anal cancers.

Many of these measures are cost-effective but remain underused in many countries because of societal, financial and political barriers.

“This updated analysis shows that the landscape of infection-related cancers continues to evolve as scientific evidence advances,” said Dr Gary Clifford, senior co-author of the study.

“It also highlights where future investments in new prevention tools could have the greatest impact, particularly for infections such as EBV, for which effective vaccines are not yet available.”

The authors said reducing infection-related cancers will require wider implementation of established prevention strategies, alongside continued investment in new tools, particularly vaccines against EBV and other cancer-causing infections for which effective preventive measures are not yet available.